Live feed12:00:00·751dPRReleasevia QuantisnowCrinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing's Syndrome (ADCS)ByQuantisnow·Wall Street's wire, on your screen.CRNX· Crinetics Pharmaceuticals Inc.Health Care
